CAR-T-Cell Therapy for Systemic Lupus Erythematosus: A Comprehensive Overview

Systemic lupus erythematosus (SLE) is a complex autoimmune disorder characterized by the production of autoreactive B and T cells and cytokines, leading to chronic inflammation affecting multiple organs. SLE is associated with significant complications that substantially increase morbidity and morta...

Full description

Saved in:

Bibliographic Details
Published in:	International journal of molecular sciences Vol. 25; no. 19; p. 10511
Main Authors:	Abdalhadi, Haneen M, Chatham, Walter W, Alduraibi, Fatima K
Format:	Journal Article
Language:	English
Published:	Switzerland MDPI AG 01-10-2024 MDPI
Subjects:	Animals Antibodies Antigens Arthritis Autoimmune diseases B cells CAR-T-cell therapy Cells Clinical trials Cytotoxicity Disease Drug therapy Federal regulation Humans Immune system Immunotherapy, Adoptive - methods Ligands Lupus Lupus Erythematosus, Systemic - immunology Lupus Erythematosus, Systemic - therapy Medical prognosis Medical research Pathogenesis Receptors, Chimeric Antigen - immunology Receptors, Chimeric Antigen - metabolism Remission (Medicine) Review Systemic lupus erythematosus T-Lymphocytes - immunology T-Lymphocytes - metabolism Transplants & implants United States CAR-T-cell therapy systemic lupus erythematosus B cells
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Systemic lupus erythematosus (SLE) is a complex autoimmune disorder characterized by the production of autoreactive B and T cells and cytokines, leading to chronic inflammation affecting multiple organs. SLE is associated with significant complications that substantially increase morbidity and mortality. Given its complex pathogenesis, conventional treatments for SLE often have significant side effects and limited efficacy, necessitating the exploration of novel therapeutic strategies. One promising approach is the use of chimeric antigen receptor (CAR)-T-cell therapy, which has shown remarkable success in treating refractory hematological malignancies. This review provides a comprehensive analysis of the current use of CAR-T-cell therapy in SLE.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23
ISSN:	1422-0067 1661-6596 1422-0067
DOI:	10.3390/ijms251910511